𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Phase I study of a 120-hour continuous intravenous infusion of 5-fluorouracil in pediatric patients with recurrent solid tumors: A pediatric oncology group study

✍ Scribed by Green, Daniel M. ;Krischer, Jeffrey P. ;Bell, Beverly ;Brecher, Martin L. ;Cushing, Barbara ;Whitehead, V. Michael

Publisher
John Wiley and Sons
Year
1990
Tongue
English
Weight
340 KB
Volume
18
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

To determine the maximum tolerated dose of 5‐fluorouracil administered as a 120‐hour continuous intravenous infusion to pediatric patients, we performed a phase I study using a starting dosage of 900 mg/m^2^/day. The maximum tolerated dosage (MTD) was 1,100 mg/m^2^/day. At this dosage level 40% of courses were complicated by grade 3 mucositis. Three additional patients were treated at the dosage level of 1,000 mg/m^2^/day after the MTD was determined. We recommend the dosage level of 1,000 mg/m^2^/day for phase II studies of 5‐fluorouracil administered as a 120‐hour continuous intravenous infusion to pediatric patients.

πŸ“œ SIMILAR VOLUMES

Phase I trial of trimetrexate in pediatr
Phase I trial of trimetrexate in pediatric solid tumors: A pediatric oncology group study
✍ Pappo, Alberto S. ;Vats, Tribhawan ;Williams, Thomas E. ;Bernstein, Mark ;Kamen, πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 283 KB

## Abstract Trimetrexate (TMTX), a lipophilic antifol, was evaluated in a Pediatric Oncology Group (POG) Phase I trial in children with refractory solid tumors. TMTX was administered intravenously daily Γ— 5 every three weeks. Starting dose was 6.4 mg/m^2^/day. Dose was escalated by 20% until the ma

5-fluorouracil and cis-platinum in the t
5-fluorouracil and cis-platinum in the treatment of refractory solid tumors: A pediatric oncology group phase I β€” II study
✍ Land, Vita J. ;Dyment, Paul G. ;Starling, Kenneth ;Strandjord, Sarah E. ;Chan, R πŸ“‚ Article πŸ“… 1981 πŸ› John Wiley and Sons 🌐 English βš– 189 KB

## Abstract Eleven patients with osteogenic sarcoma (9), Hodgkin disease (1), and mesenchymal sarcoma (1), were treated with 5‐fluorouracil (5‐FU) and cisplatin (DDP). Myelosuppression and vomiting of variable degrees occurred in all. No responses were seen.

Phase II investigation of docetaxel in p
Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors : A report from the Children's Oncology Group
✍ Ted Zwerdling; Mark Krailo; Philip Monteleone; Rebecca Byrd; Judith Sato; Rose D πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 106 KB πŸ‘ 2 views

## Abstract ## BACKGROUND Docetaxel, which is an antitubulin agent, has demonstrable activity against murine and human tumors. The current study was designed to determine response rates to docetaxel in various strata of recurrent solid tumors of childhood and to assess toxicity in a group of patie

Evaluation of low dose continuous infusi
Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group study
✍ Julie A. Kish; Michael Wolf; E. David Crawford; Joseph T. Leimert; Anton Buesche πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 289 KB πŸ‘ 2 views

Background. The response rate of metastatic renal cell cancer to cytotoxic therapy over the last 10 years has been 5.6%. Low dose continuous 5-fluorouracil(5-FU) has demonstrated efficacy in other cytotoxic refractory tumors, such as pancreas, colorectal, and recurrent breast. The Southwest Oncology